Dr. Deng is a retired medical oncology researcher from the University of California San Francisco School of Medicine (UCSF), San Francisco, California. He received his M.D. from the Peking Union Medical College, Chinese Academy of Medical Sciences. His expertises are in medical oncology and molecular biology. Dr. Deng was a Medical Doctor, Tongde Hospital, Qinghai, China 1968-1973; Research Fellow, PUMC, Chinese Academy of Med Sciences, Beijing 1973-1975; Research Associate, Beijing Institute for Cancer Research, Beijing 1975-1979; Postdoc Res Fellow, Dept of Biochemistry, Cornell University, USA, 1979-1982; Assistant Professor, Beijing Inst for Cancer Res, Beijing Medical Univ,1982-1986; Associate Professor, Beijing Inst for Cancer Res, Beijing Medical Univ, 1986-1988; Professor, Beijing Inst for Cancer Res, Beijing Medical Univ, 1988-1991.

Dr. Deng joined University of California San Francisco School of Medicine (UCSF) in 1989 and after 32 years of service he retired from the UCSF in 2021. He received several awards for his highly innovative research in medical oncology and genetics such as: Award for Developing Science and Technology, Beijing Municipal Government, 1992; Award for Developing Science and Technology, Beijing Municipal Government, 1989; Highest Award for Outstanding Academic Study, Chinese Cancer Association, 1989; Scientist with outstanding achievements, Chinese Government, 1988; Award for Developing Science and Technology, Beijing Municipal Government, 1988; Award for Developing Science and Tech, Chinese Ministry of Science and Tech, 1987; Award for Basic Research, Chinese Ministry of Health, 1986; Highest Award for Scientists, Chinese Ministry of Health and Association of Oncology, 1986; Highest Award for Developing Science and Tech, Beijing Government, 1985.

Dr. Deng was the first scientist to report loss of heterozygosity in normal tissues adjacent to breast cancer (Science 274: 2057-2059, 1996). He has published more than 200 research papers in high impact journals in the field of oncology and genetics. He has expertise in development of genetic and epigenetic biomarkers for various malignancies.